- [0033] In some embodiments the antigen-binding molecule comprises:
  - [0034] (i) a heavy chain variable (VH) region incorporating the following CDRs:
    - [0035] HC-CDR1 having the amino acid sequence of SEQ ID NO:41
    - [0036] HC-CDR2 having the amino acid sequence of SEQ ID NO:44
    - [0037] HC-CDR3 having the amino acid sequence of SEQ ID NO:47; and
  - [0038] (ii) a light chain variable (VL) region incorporating the following CDRs:
    - [0039] LC-CDR1 having the amino acid sequence of SEQ ID NO:89
    - [0040] LC-CDR2 having the amino acid sequence of SEQ ID NO:92
    - [0041] LC-CDR3 having the amino acid sequence of SEQ ID NO:95.
- [0042] In some embodiments the antigen-binding molecule comprises:
  - [0043] (i) a heavy chain variable (VH) region incorporating the following CDRs:
    - [0044] HC-CDR1 having the amino acid sequence of SEQ ID NO:41
    - [0045] HC-CDR2 having the amino acid sequence of SEQ ID NO:44
    - [0046] HC-CDR3 having the amino acid sequence of SEQ ID NO:47; and
  - [0047] (ii) a light chain variable (VL) region incorporating the following CDRs:
    - [0048] LC-CDR1 having the amino acid sequence of SEQ ID NO:90
    - [0049] LC-CDR2 having the amino acid sequence of SEQ ID NO:92
  - [0050] LC-CDR3 having the amino acid sequence of SEQ ID NO:96.
- [0051] In some embodiments the antigen-binding molecule comprises:
  - [0052] (i) a heavy chain variable (VH) region incorporating the following CDRs:
    - [0053] HC-CDR1 having the amino acid sequence of SEQ ID NO:41
    - [0054] HC-CDR2 having the amino acid sequence of SEQ ID NO:44
    - [0055] HC-CDR3 having the amino acid sequence of SEQ ID NO:47; and
  - [0056] (ii) a light chain variable (VL) region incorporating the following CDRs:
    - [0057] LC-CDR1 having the amino acid sequence of SEQ ID NO:88
    - [0058] LC-CDR2 having the amino acid sequence of SEQ ID NO:92
    - [0059] LC-CDR3 having the amino acid sequence of SEQ ID NO:98.
- [0060] In some embodiments the antigen-binding molecule comprises:
  - [0061] (i) a heavy chain variable (VH) region incorporating the following CDRs:
    - [0062] HC-CDR1 having the amino acid sequence of SEQ ID NO:41
    - [0063] HC-CDR2 having the amino acid sequence of SEQ ID NO:45
    - [0064] HC-CDR3 having the amino acid sequence of SEQ ID NO:47; and

- [0065] (ii) a light chain variable (VL) region incorporating the following CDRs:
  - [0066] LC-CDR1 having the amino acid sequence of SEQ ID NO:88
  - [0067] LC-CDR2 having the amino acid sequence of SEQ ID NO:93
  - [0068] LC-CDR3 having the amino acid sequence of SEQ ID NO:95.
- [0069] In some embodiments the antigen-binding molecule comprises:
  - [0070] (i) a heavy chain variable (VH) region incorporating the following CDRs;
    - [0071] HC-CDR1 having the amino acid sequence of SEQ ID NO:41
    - [0072] HC-CDR2 having the amino acid sequence of SEQ ID NO:45
    - [0073] HC-CDR3 having the amino acid sequence of SEQ ID NO:49; and
  - [0074] (ii) a light chain variable (VL) region incorporating the following CDRs:
    - [0075] LC-CDR1 having the amino acid sequence of SEQ ID NO:88
    - [0076] LC-CDR2 having the amino acid sequence of SEQ ID NO:93
    - [0077] LC-CDR3 having the amino acid sequence of SEQ ID NO:95.
- [0078] In some embodiments the antigen-binding molecule comprises:
  - [0079] (i) a heavy chain variable (VH) region incorporating the following CDRs:
    - [0080] HC-CDR1 having the amino acid sequence of SEQ ID NO:41
    - [0081] HC-CDR2 having the amino acid sequence of SEQ ID NO:45
    - [0082] HC-CDR3 having the amino acid sequence of SEQ ID NO:50; and
  - [0083] (ii) a light chain variable (VL) region incorporating the following CDRs:
    - [0084] LC-CDR1 having the amino acid sequence of SEQ ID NO:88
    - [0085] LC-CDR2 having the amino acid sequence of SEQ ID NO:93
  - [0086] LC-CDR3 having the amino acid sequence of SEQ ID NO:95.
- [0087] In some embodiments the antigen-binding molecule comprises:
  - [0088] (i) a heavy chain variable (VH) region incorporating the following CDRs:
    - [0089] HC-CDR1 having the amino acid sequence of SEQ ID NO:41
    - [0090] HC-CDR2 having the amino acid sequence of SEQ ID NO:45
    - [0091] HC-CDR3 having the amino acid sequence of SEQ ID NO:48; and
  - [0092] (ii) a light chain variable (VL) region incorporating the following CDRs:
    - [0093] LC-CDR1 having the amino acid sequence of SEQ ID NO:88
    - [0094] LC-CDR2 having the amino acid sequence of SEQ ID NO:92
    - [0095] LC-CDR3 having the amino acid sequence of SEQ ID NO:95.